Human caveolin-1 a potent inhibitor for prostate cancer therapy: a computational approach
by Uzma Khanam; Balwant Kishan Malik; Puniti Mathur; Bhawna Rathi
International Journal of Computational Biology and Drug Design (IJCBDD), Vol. 12, No. 3, 2019

Abstract: Caveolin-1 (Cav-1) is 22 kDa caveolae protein, acts as a scaffold within caveolar membranes, interacts with Gα-protein and thereby regulates their activity. Earlier studies reported elevated caveolin-1 levels in the serum of prostate cancer patients. Secreted Cav-1 promotes angiogenesis, cell proliferation and anti-apoptotic activities in prostate cancer patients. This study was designed to explore Cav-1 as a target for prostate cancer therapy using computational approach. Molecular docking, structural base molecular modelling and molecular dynamics simulations were performed to investigate Cav-1 inhibitors. A predictive model was used for virtual screening against ZINC database of biogenic compounds. Stability of the active site residues of Cav-1 was estimated by IFD and 100 ns long molecular dynamic simulations. The reported compounds showed significant binding and thus can be considered potent therapeutic inhibitors of Cav-1. Thus, further investigative studies on the biochemical interactions of Cav-1 would provide a valuable insight into its probable therapeutic applications.

Online publication date: Sun, 07-Jul-2019

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Computational Biology and Drug Design (IJCBDD):
Login with your Inderscience username and password:

    Username:        Password:         

Forgotten your password?

Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email